Sanofi says its GLP-1 drug, lixisenatide, performed well again in its latest phase III trial with Type 2 diabetes patients. The drug used in combination with Sanofi's Lantus (insulin) significantly lowered patient blood sugar levels and resulted in weight loss.
Analysts say that Sanofi is now positioned to have a potential blockbuster on its hands. The new drug will be marketed as Lyxumia when approved. See Fierce Biotech.
Posted by Bruce Lehr May 31st 2011.
Comments